Incidence of Hepatitis B Infection among People with Renal Failure in Babylon Province
Abstract
Introduction: This study was performed in the Marjan Medical City/ hemodialysis Center of Babylon province, Iraq from 1 February 2020 to 1 February 2021. It aimed to investigate the incidence of the hepatitis B virus in people with renal failure. The study included some factors such as virus type, seasons, gender, age group, and blood groups.
Methods: The reporting of all suspected HBV cases with renal failure in Marjan Medical City/ Haemodialysis Center in the Directorate General of Health (DGoH) of Babylon province/ Iraq from 1 February 2020 to 1 February 2021 were used in the current study.
Results: The results of this study showed that the total infection incidence in renal failure samples reached (16.67%) of 48 diseased cases that were monitored by the artificial Kidney centre (hemodialysis) for people infected with the hepatitis B virus. The prevalence of this pattern was observed during the seasons of the year, where the infection incidence was higher in June and September, amounting to 61.11% and 36.39%, respectively, while males 17.42% recorded a higher incidence of infection than it is in females 15.45%. It was found that the infection rates varied. Among the different age groups (13-68 years), the highest infection rate was within the youth age group (11-20), (21-30), and (41-50) years old, which was 66.67%, 26.67%, and 25%, respectively.
Conclusion: Subjects with HBV demonstrated that O+ and unidentified blood groups had confirmed instances of HBV contrast to other blood groups with 39.58 per cent and 29 per cent, respectively.
How to cite this article:
Imran Al-Kaif RA, Al-Mashhady FR, Drais AA, Abed AS. Incidence of Hepatitis B Infection among People with Renal Failure in Babylon Province. Special Issue - COVID-19 & Other Communicable Disease. 2022;115-119.
DOI: https://doi.org/10.24321/0019.5138.202218
References
Kappus MR, Sterling RK. Extrahepatic manifestations of acute hepatitis B virus infection. Gastroenterol Hepatol. 2013;9:123-6. [Google Scholar]
Morgan DJ, McLean AJ. Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease: an update. Clin Pharmacokinet. 1995 Nov;29(5):370-91. [PubMed] [Google Scholar]
Akkaif MA, Daud NA, Sha’aban A, Ng ML, Abdul Kader MA, Noor DA, Ibrahim B. The role of genetic polymorphism and other factors on clopidogrel resistance (CR) in an Asian population with coronary heart disease (CHD). Molecules. 2021 Apr;26(7):1987. [PubMed] [Google Scholar]
Akkaif MA, Sha’aban A, Daud NA, Ng ML, Ibrahim B. Investigate the strategy of using pharmacogenetics and pharmacometabonomics to the personalization of ticagrelor antiplatelet therapy. Syst Rev Pharm. 2020;11(9):1100-7. [Google Scholar]
Akkaif MA, Ng ML, Sk Abdul Kader MA, Daud NA, Sha’aban A, Ibrahim B. A review of the effects of ticagrelor on adenosine concentration and its clinical significance. Pharmacol Rep. 2021 Dec;73(6):1551-64. [PubMed] [Google Scholar]
Guengerich FP, Turvy CG. Comparison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples. J Pharmacol Exp Ther. 1991 Mar;256:1189-94. [PubMed] [Google Scholar]
George J, Liddle C, Murray M, Byth K, Farrell GC. Pre-translational regulation of cytochrome P450 genes is responsible for disease specific changes of individual P450 enzymes among patients with cirrhosis. Biochem Pharmacol. 1995 Mar;49:873-81. [PubMed] [Google Scholar]
George J, Murray M, Byth K, Farrell GC. Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease. Hepatology. 1995 Jan;21:120-8. [PubMed] [Google Scholar]
Lown K, Kolars J, Turgeon K, Merion R, Wrighton SA, Watkins PB. The erythromycin breath test selectively measures P450IIIA in patients with severe liver disease. Clin Pharmacol Ther. 1992 Mar;51:229-38. [PubMed] [Google Scholar]
Le V. Safe blood transfusion: screening for Hepatitis B and Hepatitis C virus infections in potential blood donors in rural Southeast Asia. Munin. 2013;23(6). [Google Scholar]
Sandhu P, Haque M, Humphries-Bickley T, Ravi S, Song J. Hepatitis B immunopathology, odel systems, and current therapies. Front Immunol. 2017 Apr;8:436. [PubMed] [Google Scholar]
Al-Shalah SA, Abood DA, Al-Zamali SK, Nasser IH, Al-Kaif LA. Study of immune status for Rubella, Cytomegalovirus, Hepatitis B Virus, and Toxoplasma gondii in Sera of University Students. Indian J Forensic Med Tox. 2021;15(3):1609. [Google Scholar]
Dikici B, Uzun H, Gozu A, Fidan M. Prevalence of Hepatitis B Infection among School children in Southeast Turkey. Turkey J Med Sci. 2009;39(2):289-93. [Google Scholar]
Ayodele OE, Salako BL, Kadiri S, Arije A, Alebiosu CO.Hepatitis B virus infection: implications in chronic kidney disease, dialysis and transplantation. Afr J Med Med Sci. 2006 Jun;35(2):111-9. [PubMed] [Google Scholar]
Williams and Wilkins. Hepatitis B. J Gastroenterol. 2005;21(3):300-7.
Buggs AM. The epidemiology of hepatitis virus. Med Clin J. 2006:1-10.
Abate M, Wolde T. Seroprevalence of human immunodeficiency virus, hepatitis B virus, hepatitis C virus, and syphilis among blood donors at Jigjiga blood bank, eastern Ethiopia. Ethiop J Health Sci. 2016;26(2):155-62. [Google Scholar]
Lao TT, Sahota DS, Chung MK, Cheung TK, Cheng YK, Leung TY. Maternal ABO and rhesus blood group phenotypes and hepatitis B surface antigen carriage. J Viral Hepat. 2014 Nov;21(11):818-23. [PubMed] [Google Scholar]
Liu J, Zhang S, Liu M, Wang Q, Shen H, Zhang Y. Distribution of ABO/Rh blood groups and their association with hepatitis B virus infection in 3.8 million Chinese adults: a population-based cross-sectional study. J Viral Hepat. 2018 Apr;25(4):401-11. [PubMed] [Google Scholar]
Copyright (c) 2022 Author's
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
